Navigation Links
CryoLife anuncia el primer implante europeo del injerto HeRO
Date:7/31/2013

#160;Society for Vascular Surgery y de la American Medical Association. Si desea más información en torno al injerto HeRO Graft, visite www.herograft.com. Si desea información adicional en relación a CryoLife, visite la página web de la compañía en: www.cryolife.com.

Las declaraciones realizadas en este comunicado de prensa que se refieren a un futuro o que expresan creencias, expectativas o esperanzas de la dirección, son declaraciones prospectivas dentro de la Private Securities Litigation Reform Act de 1995. Estas declaraciones reflejan las visiones del equipo administrativo en el momento de realización de las declaraciones, estando sujetas a riesgos, incertidumbres, estimaciones y presunciones que podrían hacer que los resultados reales difieran materialmente de las expectativas reales. Estas declaraciones incluyen las relacionadas con nuestras creencias de que el injerto HeRO será un impulsor de crecimiento para la compañía. El impacto del injerto HeRO para nuestro crecimiento está sujeto a riesgos e incertidumbres, incluyendo que los médicos y pacientes puedan no aceptar el injerto HeRO como opción de tratamiento viable, que los reguladores puedan retirar las aprobaciones existentes o imponer condiciones adicionales para el uso del injerto HeRO, implantes futuros que puedan no tener éxito o complicaciones que pudieran surgir tras el implante, condiciones económicas en la UE que pudieran impactar en la decisión de uso del injerto HeRO basándose en su coste, productos competitivos que pudieran demostrar ser más eficaces o costar menos y la reciente incapacidad de la compañía de importar los tejidos en la UE que pudiera impactar en las decisiones de uso del injerto HeRO. CryoLife está sujeta también a los riesgos generales asociados a nu
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
2. CryoLife Completes Acquisition of Hemosphere
3. CryoLife to Participate in 3rd Annual Benchmark Company, LLC One-on-One Investor Conference
4. CryoLife Announces Release Date and Teleconference Call Details for 2012 Second Quarter Financial Results
5. CryoLife Reports 13% Revenue Growth for Second Quarter 2012
6. CryoLife Announces Initiation of Quarterly Cash Dividend
7. CryoLife Reports 13% Revenue Growth for Third Quarter 2012
8. CryoLife to Participate in Lazard Capital Markets 9th Annual Healthcare Conference
9. CryoLife Receives Expanded Indication for BioFoam in Europe
10. CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
11. CryoLife Announces Quarterly Cash Dividend for the First Quarter 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... PLYMOUTH MEETING, Pa. , Sept. 22, 2014 ... ) announced today it has initiated a phase ... The trial will evaluate the safety, tolerability, and ... type 6 (HPV-6), which causes most aerodigestive cancers. ... tongue, nose, throat, vocal cords, and parts of ...
(Date:9/22/2014)... and NEW YORK , Sept. ... ACCP), has signed an exclusive, global license agreement ... and commercialization of its proprietary plasma fractionation process. ... team and its intention to strategically refocus and ... its plans to pursue a national listing for ...
(Date:9/22/2014)... Pa. , Sept. 22, 2014 ... a specialty biopharmaceutical company, today announced that its ... unsolicited, non-binding and conditional proposal from Endo International ... financial and legal advisors, has unanimously determined it ... of its existing merger agreement with QLT Inc. ...
Breaking Medicine Technology:Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6Auxilium Provides Transaction Update 2Auxilium Provides Transaction Update 3Auxilium Provides Transaction Update 4Auxilium Provides Transaction Update 5Auxilium Provides Transaction Update 6
... SAN DIEGO, Feb. 6, 2012 Amylin Pharmaceuticals, Inc. (Nasdaq: ... quarter and year ended December 31, 2011. ... $164.9 million, which included net product sales of $160.9 million. ... 2011 was $17.6 million, compared to a non-GAAP operating income ...
... Feb. 6, 2012  Genomic Health, Inc. (Nasdaq: GHDX ... with the goal of improving the quality of diagnosis, communication ... with common and rare genetic conditions.   The subsidiary is expected ... first commercial service in 2013.  The new venture will be ...
Cached Medicine Technology:Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 2Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 3Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 4Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 5Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 6Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 7Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 8Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results 9Genomic Health Announces Formation of New Genetics Subsidiary 2Genomic Health Announces Formation of New Genetics Subsidiary 3Genomic Health Announces Formation of New Genetics Subsidiary 4
(Date:9/22/2014)... NY (PRWEB) September 22, 2014 ... whom all of the federal mesh lawsuits ( ... Corp. have been consolidated for pretrial matters, issued ... Scientific Corp. Pelvic Repair System Products Liability Litigation ... of West Virginia; Case no. 2:12-md-02326)—requiring that four ...
(Date:9/22/2014)... -- All sexually active women should be screened ... infections: chlamydia and gonorrhea, according to new recommendations ... The task force noted this recommendation includes ... age and pregnant women. Most women with ... a result, many infections go undetected. If left ...
(Date:9/22/2014)... Steven Reinberg HealthDay Reporter ... are urging that all children aged 6 months and older ... Academy of Pediatrics updated their influenza vaccine recommendations to advise ... vaccine to build immunity. The AAP also wants parents of ... the nasal spray vaccine instead of the flu shot if ...
(Date:9/22/2014)... Hamilton, ON (September 22, 2014) McMaster scientists have ... a new class of antibiotics. , Although dozens ... looked at how a certain part of bacteria are ... stopping it. , The discovery is important as ... is making the cures for infections ineffective. The World ...
(Date:9/22/2014)... September 22, 2014 Quincy Bioscience, ... United States, promotes National Self-Improvement Month ... all individuals should have access to self-improvement resources, ... , The demand for products that preserve health ... ever before. For over six years, Quincy Bioscience ...
Breaking Medicine News(10 mins):Health News:Federal Court Sets Trial Date for Boston Scientific Vaginal Mesh Cases in Florida, the Rottenstein Law Group LLP Reports 2Health News:Screen Women for Chlamydia, Gonorrhea, Experts Say 2Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 2Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 3Health News:Quincy Bioscience Promotes National Self-Improvement Month 2
... Dramatically Cut Largest Source of Deadly Diesel Pollution in State ... 12 The California Air Resources Board today approved two ... of diesel pollution in the state and are the first ... Defense Fund (EDF). The Air Resource Board estimates that the ...
... national partners in effort to raise $5 million , ... National partners from the 17th annual Halloween Promotion benefiting ... celebrate raising more than $2.4 million to help the hospital ... , Companies represented at today,s recognition ceremony ...
... cells may make them more resilient during real attack, experts ... have long known that the creation of a "mini ... flow to arteries -- can actually reduce the damage from ... how that protective effect occurs, according to research from the ...
... PartsSource, the nation,s leading,supplier of replacement medical repair parts for ... in Ohio by the Case Western Reserve,University Weatherhead ... placed 14th on this year,s list with a growth rate ... eligible. , "The Weatherhead ...
... to bad treatment decisions, study shows , , FRIDAY, ... receive about the risk of their breast cancer ... whether to get chemotherapy more difficult, a new ... patients a bar chart, based on a standard ...
... A new report from the Institute of Medicine, THE ... ADMINISTRATION, examines why a commitment to global health is ... light of the current economic situation. The report ... goals the incoming administration should strive to meet, and ...
Cached Medicine News:Health News:California Rules to Cut Diesel Truck Pollution Called Most Sweeping in U.S. 2Health News:More Than $2.4 Million Raised by National Halloween Promotion Partners to Help St. Jude Fight Childhood Cancer 2Health News:Research Explains Benefit of 'Mini Heart Attack' 2Health News:Risk Info for Breast Cancer Patients Too Confusing 2
... EXPRESS Seeding Cartridge System is a single-use, ... seeds and spacers into a Bard BrachyStar ... has a(n): outer radiation safety shield, inner ... spacers, integrally molded fitting that connects the ...
... very easy to use Ambulatory Urodynamic recorder ... with practising urologists as an invaluable aid ... dysfunctions. The system offers the possibility to ... a natural bladder filling, extented over a ...
A compact mobile System Cart gives mobility within your department. The cart accomodates the Uromac Median data processor, desktop computer, printer and provides stowage space. Patient related transd...
... with state of the art software that ... meet the needs of your busy center. ... upgraded to grow with you. With optional ... it is easy to see why Dorado™ ...
Medicine Products: